New Treanda Liquid Formulation Eliminates Reconstitution Step

Share this content:
Teva announced the availability of a new liquid formulation of Treanda (bendamustine HCl) injection.
Teva announced the availability of a new liquid formulation of Treanda (bendamustine HCl) injection.

Teva announced the availability of a new liquid formulation of Treanda (bendamustine HCl) Injection. 

Prior to the new formulation approval, Treanda was available as vials containing lyophilized powder for reconstitution.

The liquid formulation now removes the reconstitution step, reducing the preparation time for healthcare professionals. The liquid formulation will be replacing the lyophilized powder formulation moving forward. 

Treanda is an alkylating agent approved for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab–containing regimen.

RELATED: New Strategy to Classify Differences in Risk for Chronic Lymphocytic Leukemia

The exact mechanism of action is unknown but bendamustine is thought to be active against both quiescent and dividing cells. Preclinical studies suggest that it may lead to cell death by a process known as apoptosis as well as by an alternate cell death pathway which disrupts normal cell division known as mitotic catastrophe. 

https://ssl.gstatic.com/ui/v1/icons/mail/images/cleardot.gifTreanda Injection is supplied as a 90mg/mL strength in 45mg/0.5mL and 180mg/2mL single-use vials. 

For more information call (800) 896-5855 or visit Treanda.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs